Anergis
Anergis is a clinical stage Swiss biotech developing breakthrough allergy vaccines for ultra-fast and safe desensitisation in only 2 months
- Stage Product In Development
- Industry Biotechnology
- Location Chemin des Croisettes, Epalinges, VD, Switzerland
- Currency CHF
- Founded June 2001
- Employees 10
- Website anergis.ch
Company Summary
Anergis SA discovers and develops breakthrough allergy vaccines targeting the most frequent allergies, based on its proprietary Continuous Overlapping Peptides technology. Anergis lead-product is in Phase IIb clinical development with efficacy and safety results expected by August-Sept 2013. Anergis has two more allergy vaccines in preclinical development against house dust mites allergy and ragweed allergy.
Team
-
Vincent CharlonCEO
CEO Anergis since 2009
CEO LS Pharma 2007-2008
CEO Hesperion (CRO) 1998-2007
Clinical Director Roche USA 1994-1998
Clinical Scientist Roche Basel CH 1990-1993
Clinical Scientist, Eliac Phase I Unit, FranceAt Hesperion, completed two acquisitions/integrations and the trade sale of Hesperion. Developed Hesperion from 1 to 200 employees in 8 countries.
-
Christophe ReymondCSO
CSO Anergis since 2005
2005-2008 CSO and COO of Anergis
CSO and co-founder of RMF Dictagene 1991-2005
Professor of Cellular Biology, University of Medecine, LausanneSpecialized in immunology, allergy, long peptides ; long-standing experience in biotech start-ups and research environment.
-
Jean Paul RohmerDirector Business Development
joined Anergis in 2009
since 2000 Managing Director IDEFI Gestion (Advice and interim management for biotechs and for biotech investors)
1994-1999 CEO Stallergenes SA, France
1979-1994 Eli Lilly Pharma France, Head of Pharma Division in the last two yearsVast experience in Pharma and biotech management, marketing as well as specifcally in allergen immmunotherapy while at Stallergenes
-
Francois SpertiniAllergy Medical Expert
Professor of Medecine
Chief Immunology/Allergology University Hosptial Lausanne Switzerland
Founder of Anergis SA in 2001.
Advisors
-
Carrard et Associés, LausanneLawyerUnconfirmedErnst & YoungAccountantUnconfirmed
Previous Investors
-
BioMedInvest, Sunstone Capital, Renaissance PME/Vinci CapitalUnconfirmedEsperante Ventures, Defi Gestion/Initiative Capital RomandieUnconfirmedPrivate investorsUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.